AFP and hepatocellular carcinoma: However, the clinical value of AFP, also referred to as the ‘gold-standard’ biomarker of HCC, remains controversial, as elevated AFP levels are often detected in patients with benign liver disease and additional malignancies, but not in a large proportion of early-stage HCCs (18).